Business● LowSep 3 · Sep 3, 2026, 5:10 PM
Moderna slips as Rothschild issues rare Sell rating after cancer vaccine-led rally
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Moderna's stock declined after Rothschild issued a rare 'Sell' rating following a rally driven by cancer vaccine news. This indicates a notable shift in analyst sentiment for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business11m agoResearch Frontiers expects material royalty recovery after Q4 2026 as Gauzy restarts SPD productionSeeking Alpha TechBusiness14m agoNerdWallet expects Q4 revenue of $191M-$203M amid auto insurance monetization challengesSeeking Alpha TechBusiness37m agoThe AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%CNBCBusiness39m agoMy grandmother spent her life caring for others. Finding care for her changed my directionMexico News Daily